These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36605847)

  • 21. Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults.
    McDonnell AM; Lenz KL; Frei-Lahr DA; Hayslip J; Hall PD
    Pharmacotherapy; 2006 Jun; 26(6):806-12. PubMed ID: 16716134
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of Single Dose Rasburicase (1.5 mg) for Prophylaxis and Management of Laboratory Tumor Lysis Syndrome.
    Philips A; Radhakrishnan V; Ganesan P; Ganesan TS; Ramamurthy J; Dhanushkodi M; Sagar TG
    Indian J Hematol Blood Transfus; 2018 Oct; 34(4):618-622. PubMed ID: 30369730
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rasburicase for the treatment of tumor lysis in hematological malignancies.
    Malaguarnera G; Giordano M; Malaguarnera M
    Expert Rev Hematol; 2012 Feb; 5(1):27-38. PubMed ID: 22272702
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor Lysis Syndrome Rare Presentation As Uremic Pericarditis: A Case Report.
    Caleça Emidio F; Pereira R; Martins Dos Santos P; Abegão T
    Cureus; 2023 Mar; 15(3):e35727. PubMed ID: 36875257
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor lysis syndrome, acute kidney injury and disease-free survival in critically ill patients requiring urgent chemotherapy.
    Abdel-Nabey M; Chaba A; Serre J; Lengliné E; Azoulay E; Darmon M; Zafrani L
    Ann Intensive Care; 2022 Feb; 12(1):15. PubMed ID: 35166948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis.
    Goldman SC; Holcenberg JS; Finklestein JZ; Hutchinson R; Kreissman S; Johnson FL; Tou C; Harvey E; Morris E; Cairo MS
    Blood; 2001 May; 97(10):2998-3003. PubMed ID: 11342423
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Single-Dose Rasburicase Might Be Adequate To Overcome Tumor Lysis Syndrome In Hematological Malignancies.
    Yaman S; Başcı S; Turan G; Ulu BU; Yiğenoğlu TN; Dal MS; Kızıl Çakar M; Altuntaş F
    Clin Lymphoma Myeloma Leuk; 2022 Feb; 22(2):e71-e76. PubMed ID: 34565690
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rasburicase-Induced Methemoglobinemia in a Patient with Aggressive Non-Hodgkin's Lymphoma.
    Alessa MA; Craig AK; Cunningham JM
    Am J Case Rep; 2015 Sep; 16():590-3. PubMed ID: 26334783
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Benefit of continuous kidney replacement therapy for managing tumor lysis syndrome in children with hematologic malignancies.
    Anderson A; Shoulders L; James V; Ashcraft E; Cheng C; Ribeiro R; Elbahlawan L
    Front Oncol; 2023; 13():1234677. PubMed ID: 37664024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness analysis of rasburicase over standard of care for the prevention and treatment of tumor lysis syndrome in children with hematologic malignancies in China.
    Hu S; Han Y; Zhang W; Zhang T; Yao X; Liu L
    J Med Econ; 2019 Aug; 22(8):742-750. PubMed ID: 30939962
    [No Abstract]   [Full Text] [Related]  

  • 31. Management of hyperuricemia with rasburicase review.
    de Bont JM; Pieters R
    Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1431-40. PubMed ID: 15571272
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment-naïve spontaneous tumor lysis syndrome in metastatic prostate adenocarcinoma: An unusual suspect.
    Ignaszewski M; Kohlitz P
    Am J Emerg Med; 2017 Sep; 35(9):1384.e1-1384.e2. PubMed ID: 28587951
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients.
    Vines AN; Shanholtz CB; Thompson JL
    Ann Pharmacother; 2010 Oct; 44(10):1529-37. PubMed ID: 20841516
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome.
    Knoebel RW; Lo M; Crank CW
    J Oncol Pharm Pract; 2011 Sep; 17(3):147-54. PubMed ID: 20332174
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pitfalls, prevention, and treatment of hyperuricemia during tumor lysis syndrome in the era of rasburicase (recombinant urate oxidase).
    Pession A; Melchionda F; Castellini C
    Biologics; 2008 Mar; 2(1):129-41. PubMed ID: 19707436
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of i.v. allopurinol and rasburicase in tumor lysis syndrome.
    Holdsworth MT; Nguyen P
    Am J Health Syst Pharm; 2003 Nov; 60(21):2213-22; quiz 2223-4. PubMed ID: 14619112
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Single 6-mg dose of rasburicase: The experience in a large academic medical center.
    Nauffal M; Redd R; Ni J; Stone RM; DeAngelo DJ; McDonnell AM
    J Oncol Pharm Pract; 2019 Sep; 25(6):1349-1356. PubMed ID: 30111244
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Case Report of Newly Diagnosed Epithelial Ovarian Carcinoma Presenting with Spontaneous Tumor Lysis Syndrome and Its Successful Management with Rasburicase.
    Shukla DK; Gupta D; Aggarwal A; Kumar D
    Indian J Med Paediatr Oncol; 2017; 38(3):360-362. PubMed ID: 29200691
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study.
    Coiffier B; Mounier N; Bologna S; Fermé C; Tilly H; Sonet A; Christian B; Casasnovas O; Jourdan E; Belhadj K; Herbrecht R;
    J Clin Oncol; 2003 Dec; 21(23):4402-6. PubMed ID: 14581437
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clarifying the role of rasburicase in tumor lysis syndrome.
    Sood AR; Burry LD; Cheng DK
    Pharmacotherapy; 2007 Jan; 27(1):111-21. PubMed ID: 17192165
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.